The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
A Phase II Pilot Trial to Estimate Survival After a Non-total Body Irradiation (TBI) Based Conditioning Regimen in Patients Diagnosed With B-acute Lymphoblastic Leukemia (ALL) Who Are Pre-allogeneic Hematopoietic Cell Transplantation (HCT) Next-generation-sequence (NGS) Minimal Residual Disease (MRD) Negative
Sponsor: Pediatric Transplantation & Cellular Therapy Consortium
This PHASE2 trial investigates B-cell Acute Lymphoblastic Leukemia and is currently actively recruiting participants. Pediatric Transplantation & Cellular Therapy Consortium leads this study, which shows 14 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Recruiting PHASE2
-
Jun 2025 — Sep 2025 [monthly]
Recruiting PHASE2
-
Sep 2024 — Jun 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Sep 2021 — Jul 2024 [monthly]
Recruiting PHASE2
▶ Show 9 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Sep 2019 — Mar 2020 [monthly]
Recruiting PHASE2
-
Feb 2019 — Sep 2019 [monthly]
Recruiting PHASE2
-
Nov 2018 — Feb 2019 [monthly]
Recruiting PHASE2
-
Sep 2018 — Nov 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Aug 2018 — Sep 2018 [monthly]
Not Yet Recruiting PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Not Yet Recruiting PHASE2
-
May 2018 — Jun 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Pediatric Transplantation & Cellular Therapy Consortium
For direct contact, visit the study record on ClinicalTrials.gov .